These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 26797975)

  • 1. A Bayesian Approach to Residual Host Cell DNA Safety Assessment.
    Yang H; Zhang J
    PDA J Pharm Sci Technol; 2016; 70(2):157-62. PubMed ID: 26797975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishing acceptable limits of residual DNA.
    Yang H
    PDA J Pharm Sci Technol; 2013; 67(2):155-63. PubMed ID: 23569076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A probabilistic model for risk assessment of residual host cell DNA in biological products.
    Yang H; Zhang L; Galinski M
    Vaccine; 2010 Apr; 28(19):3308-11. PubMed ID: 20226252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A statistical approach to determining criticality of residual host cell DNA.
    Yang H; Wei Z; Schenerman M
    J Biopharm Stat; 2015; 25(2):234-46. PubMed ID: 25358029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Model of Risk Analysis in Analytical Methodology for Biopharmaceutical Quality Control.
    Andrade CL; Herrera MAO; Lemes EMB
    PDA J Pharm Sci Technol; 2018; 72(3):317-331. PubMed ID: 29444996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety issues relating to the use of mammalian cells as hosts.
    Petricciani JC
    Dev Biol Stand; 1985; 59():149-53. PubMed ID: 3891461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Bayesian Approach to Determination of
    Faya P; Stamey JD; Seaman JW
    PDA J Pharm Sci Technol; 2017; 71(2):88-98. PubMed ID: 27789802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Use of Bayesian Hierarchical Logistic Regression in the Development of a Modular Viral Inactivation Claim.
    Banton D; Vacante D; Bulthuis B; Goldstein J; Wineburg M; Schreffler J
    PDA J Pharm Sci Technol; 2019; 73(6):552-561. PubMed ID: 31101710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sources, pathways, and relative risks of contaminants in surface water and groundwater: a perspective prepared for the Walkerton inquiry.
    Ritter L; Solomon K; Sibley P; Hall K; Keen P; Mattu G; Linton B
    J Toxicol Environ Health A; 2002 Jan; 65(1):1-142. PubMed ID: 11809004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel Method for Calculating a Nonsubjective Informative Prior for a Bayesian Model in Toxicology Screening: A Theoretical Framework.
    Woldegebriel M
    Anal Chem; 2015 Nov; 87(22):11398-406. PubMed ID: 26482700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Part 2. Development of Enhanced Statistical Methods for Assessing Health Effects Associated with an Unknown Number of Major Sources of Multiple Air Pollutants.
    Park ES; Symanski E; Han D; Spiegelman C
    Res Rep Health Eff Inst; 2015 Jun; (183 Pt 1-2):51-113. PubMed ID: 26333239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using full probability models to compute probabilities of actual interest to decision makers.
    Harrell FE; Shih YC
    Int J Technol Assess Health Care; 2001; 17(1):17-26. PubMed ID: 11329842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Creating a Holistic Extractables and Leachables (E&L) Program for Biotechnology Products.
    Li K; Rogers G; Nashed-Samuel Y; Lee H; Mire-Sluis A; Cherney B; Forster R; Yeh P; Markovic I
    PDA J Pharm Sci Technol; 2015; 69(5):590-619. PubMed ID: 26429108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bayesian Networks Improve Causal Environmental Assessments for Evidence-Based Policy.
    Carriger JF; Barron MG; Newman MC
    Environ Sci Technol; 2016 Dec; 50(24):13195-13205. PubMed ID: 27993076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bayesian assurance and sample size determination in the process validation life-cycle.
    Faya P; Seaman JW; Stamey JD
    J Biopharm Stat; 2017; 27(1):159-174. PubMed ID: 26891342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bayesian analysis of time-series data under case-crossover designs: posterior equivalence and inference.
    Li S; Mukherjee B; Batterman S; Ghosh M
    Biometrics; 2013 Dec; 69(4):925-36. PubMed ID: 24289144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simple Approach to Calculate Random Effects Model Tolerance Intervals to Set Release and Shelf-Life Specification Limits of Pharmaceutical Products.
    Montes RO; Burdick RK; Leblond DJ
    PDA J Pharm Sci Technol; 2019; 73(1):39-59. PubMed ID: 30361286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-normal random effects models for immunogenicity assay cut point determination.
    Zhang J; Yu B; Zhang L; Roskos L; Richman L; Yang H
    J Biopharm Stat; 2015; 25(2):295-306. PubMed ID: 25356500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of Bayesian estimation of pharmacokinetic parameters.
    Tsuchiwata S; Mihara K; Yafune A; Ogata H
    Ther Drug Monit; 2005 Feb; 27(1):18-24. PubMed ID: 15665741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Bayesian approach to utilizing prior data in new drug development.
    Shen LZ; Coffey T; Deng W
    J Biopharm Stat; 2008; 18(2):227-43. PubMed ID: 18327718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.